Data content management will drive the growing global data and analytics market in the pharmaceutical sector, which will reach a valuation of $2.1bn by 2028, according to a report. The 2024 edition of ...
The detailed results from the HARMONi trial—the first global phase 3 data set for the world’s first PD-1xVEGF bispecific, ivonescimab—have sparked a mix of hopes and concerns, leading to a 25% stock ...
Define Ventures’ new report provides a clear framework for how enterprise healthcare, particularly Big Pharma, is transitioning from AI exploration to execution. It focuses on core categories, ...
For pharmaceutical firms, watching the lucrative patents on their top-selling drugs expire has long been part of the business ...
In this special guest feature, Inga Shugalo, a Healthcare Industry Analyst at Itransition, suggests that whether it’s an application for precision medicine, decreasing the failure rates in drug trials ...
Still life of Ozempic and Wegovy. Both are injectable prescription weight loss medicines. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) As demand surges for semaglutide ...
Genetic sequencing company Illumina (ILMN) has had a rough few years. It has battled activist investors, faced off with the Federal Trade Commission, and, most recently, agreed to a $9.8 million ...
In this special guest feature, John Hogan, Senior Vice President of Engineering at TraceLink, discusses the pharmaceutical supply chain, and the challenges it is facing regarding big data and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback